DeCure for Trichomegaly-retina pigmentary degeneration-dwarfism syndrome
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for trichomegaly-retina pigmentary degeneration-dwarfism syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTrichomegaly-retina pigmentary degeneration-dwarfism syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for trichomegaly-retina pigmentary degeneration-dwarfism syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Three patients described in 1971 had abnormally long but sparse eyelashes and brows (congenital trichomegaly), noninflammatory pigmentary degeneration of the retina, and sustained growth retardation that began before birth. No chromosomal defect or familial inheritance pattern was identified. The authors stated that further clarification of the genetics and the basis for the mental retardation would require study of additional cases. An earlier 1958 report noted that pigmentary degeneration of the retina can occur with external ophthalmoplegia and complete heart block, and that the Lawrence-Moon-Biedl syndrome combines retinal degeneration with obesity, mental retardation, hypogenitalism, and polydactyly; other less common associations included deafness, convulsions, cerebellar ataxia, and progeria.
A separate 1986 case report described an 11-year-old girl with severe pigmentary degeneration of the retina, severe musculoskeletal abnormalities, growth failure, recurrent respiratory problems, sensorineural hearing loss, and mental retardation. The authors considered this a probable new clinical entity not previously described. No drug treatment was mentioned in any of these reports.
No therapy has been tested for this syndrome. What is missing is any systematic collection of cases, any natural history study, any genetic characterisation, and any funding for such work. Without patient registries and molecular diagnosis, no trial design is possible, and no stratification by genotype or phenotype can begin.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
A M A Archives of Ophthalmology · 1958 · 624 citations
Retinitis Pigmentosa, External Ophthalmoplegia, and Complete Heart Block
AbstractPigmentary degeneration of the retina (retinitis pigmentosa) may appear as an isolated finding unassociated with other systemic abnormalities. Often, however, the patient may present other abnormalities, a number of which occur frequently enough in association with retinitis pigmentosa to be recognized as a syndrome. The Lawrence-Moon-Biedl syndrome, consisting of pigmentary degeneration of the retina, obesity, mental retardation, hypogenitalism, and polydactyly, is such an example. There also may be other less common abnormalities, such as deafness, convulsions, ophthalmoplegia, cerebellar ataxia, and progeria (premature aging) associated with retinitis pigmentosa. External ophthalmoplegia is one of the uncommoner abnormalities found associated with pigmentary degeneration of the retina. Barnard and Scholz<sup>1</sup>reported four cases of this association and concluded that the association was more than just coincidental. Walsh<sup>2</sup>agreed with them and stated that the association is not just fortuitous but rather represents a syndrome. He listed five cases that he had observed,
American journal of diseases of children · 1971 · 26 citations
Trichomegaly, Pigmentary Degeneration of the Retina, and Growth Retardation
AbstractThree patients appear to represent a new syndrome of unknown etiology, manifested by abnormally long but sparse eyelashes and brows (congenital trichomegaly), noninflammatory pigmentary degeneration of the retina, and sustained growth retardation originating in utero. The syndrome does not appear to be associated with a recognizable chromosomal defect nor with a familial pattern of inheritance. Further clarification of the genetics of this disorder and of the basis for the mental retardation will require study of additional cases.
Ophthalmic Paediatrics and Genetics · 1986 · 8 citations
Tapetoretinal degeneration associated with multisystem abnormalities: A case report
AbstractTapetoretinal degeneration is not infrequently associated with other systemic abnormalities. The authors have examined an 11-year-old girl with severe pigmentary degeneration of the retina associated with severe musculoskeletal abnormalities, growth failure, recurrent respiratory problems, sensorineural hearing loss, and mental retardation. To the best of their knowledge, this constellation of features has not been described previously and probably represents a new clinical entity.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
